Login to Your Account

Deep product portfolio for anti-PD-1 immunotherapies

Monday, March 10, 2014

As we described in last week’s issue there is no doubt that agents that target the PD-1 pathway have generated much excitement among investors. There are several candidate drugs in late-stage development as anti-PD-1 immunotherapies targeting various solid cancers such as melanoma. In addition to the pharma players in this space, a number of biotech companies are focusing on this pathway. Many of their compounds are still at the early discovery and preclinical stages, but they are already showing potential.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription